| DB ID | MyCo_7246 |
| Title | A score for predicting invasive pulmonary aspergillosis in immunocompetent critically ill patients |
| Year | 2023 |
| PMID | 36920323 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | This study was approved by ethics committee of Xiangya Hospital, Central South University (No. 202104005). |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | PNI |
| Biomarker Full Name | Prognostic nutritional index |
| Biomarker Type | Diagnostic |
| Biomolecule | None |
| Geographical Location | China |
| Cohort | Here screened 2546 consecutive patients admitted to the ICU, excluding 705 patients, and enrolled 1841 patients in this study . |
| Cohort No. | 1841 |
| Age Group | None |
| P Value | p=.002 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive pulmonary aspergillosis (IPA) is a life-¬ threatening opportunistic fungal infection with a high mortality rate ranging from 45% to 90%. It mostly occurs in immuno- suppressed patients, such as those with haematological malignancies, solid organ transplants or prolonged neu- tropenia. IPA has also been accepted as an emerging in- fection in critically ill patients admitted to the intensive care unit (ICU). Critically ill patients admitted to the ICU are often exposed to many risk factors associated with IPA, such as the use of invasive devices, prolonged ex- posure to corticosteroids or broad-¬ spectrum antibiotics. The incidence of IPA in ICU settings fluctuates from 0.2% to 39%, with an overall mortality rate exceeding 60%. However, previous studies and clinical guidelines have mostly focused on immunodeficient patients and may not be applicable to patients in the ICU, because most patients in the ICU have a normal immune status at the onset of infection. Hence, there is a lack of strong clinical evidence to guide the early diagnosis of IPA and subsequent timely initial antifungal therapy in immunocompetent patients in the ICU. |
| Technique | None |
| Analysis Method | None |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | None |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
